(Q35005940)

5 August 2017

1 reference

title

Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction (English)

1 reference

5 August 2017

7

Roberta Mortarini

1 reference

5 August 2017

Veronica Huber

3

0 references

Piero Dalerba

Piero Dalerba

6

0 references

Chiara Castelli

Chiara Castelli

4

0 references

Stefano Fais

Stefano Fais

10

0 references

Andrea Anichini

Andrea Anichini

9

0 references

Licia Rivoltini

Licia Rivoltini

1

0 references

author name string

Matteo Carrabba

2

1 reference

5 August 2017

Luisa Novellino

5

1 reference

5 August 2017

Giuseppe Arancia

8

1 reference

5 August 2017

Giorgio Parmiani

11

1 reference

5 August 2017

publication date

1 October 2002

1 reference

5 August 2017

published in

Immunological Reviews

1 reference

5 August 2017

volume

188

1 reference

5 August 2017

page(s)

97-113

1 reference

New paths in human cancer serology

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

Regulation of KIR expression in human T cells: a safety mechanism that may impair protective T-cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

NKT cells - conductors of tumor immunity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

A listing of human tumor antigens recognized by T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillanc

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

A natural cytotoxic T cell response in a spontaneously regressing human melanoma targets a neoantigen resulting from a somatic point mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

High frequency of autologous anti-melanoma CTL directed against an antigen generated by a point mutation in a new helicase gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

In vivo activation of melanoma-specific CD8(+) T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus-specific T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

Apoptosis by death factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

The role of FasL-induced apoptosis in immune privilege

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

The Fas counterattack: cancer as a site of immune privilege

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

Countering the 'counterattack' hypothesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

Tumor-infiltrating lymphocytes: their phenotype, functions and clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

Expressions of Fas ligand and other apoptosis-related genes and their prognostic significance in epithelial ovarian neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

Degranulation plays an essential part in regulating cell surface expression of Fas ligand in T cells and natural killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

Lysosome-related organelles

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

Cutting Edge: The Tumor Counterattack Hypothesis Revisited: Colon Cancer Cells Do Not Induce T Cell Apoptosis Via the Fas (CD95, APO-1) Pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

Fas and Fas ligand interactions suppress melanoma lung metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

Fas and FasL in the homeostatic regulation of immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

Resistance to fas-mediated apoptosis of peripheral T cells in human T lymphocyte virus type I (HTLV-I) transgenic mice with autoimmune arthropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

Essential flexibility in the T-cell recognition of antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

Tickling the TCR: selective T-cell functions stimulated by altered peptide ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

Altered peptide ligand-induced partial T cell activation: molecular mechanisms and role in T cell biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

Thymic selection generates a large T cell pool recognizing a self-peptide in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

Class I major histocompatibility complex anchor substitutions alter the conformation of T cell receptor contacts

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

Amino Acid Substitutions in the Melanoma Antigen Recognized by T Cell 1 Peptide Modulate Cytokine Responses in Melanoma-Specific T Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

Rexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2'-deoxycytidine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

Selective histocompatibility leukocyte antigen (HLA)-A2 loss caused by aberrant pre-mRNA splicing in 624MEL28 melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

Antigen-processing machinery breakdown and tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

Inhibition of death receptor signals by cellular FLIP

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

The biochemistry of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

Granzyme B induces BID-mediated cytochrome c release and mitochondrial permeability transition

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

Nitric oxide and the regulation of gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

S-nitrosylation regulates apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

Nitric oxide-mediated regulation of chemosensitivity in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

Nitric oxide inhibits Fas-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

Fas-induced caspase denitrosylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

Differential Anti-MART-1/MelanA CTL Activity in Peripheral Blood of HLA-A2 Melanoma Patients in Comparison to Healthy Donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

7 January 2021

Primary melanoma tumour regression associated with an immune response to the tumour-associated antigen melan-A/MART-1

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

7 January 2021

A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

7 January 2021

A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

7 January 2021

Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

7 January 2021

Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

7 January 2021

Die and let live: eliminating dangerous lymphocytes

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

7 January 2021

Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

7 January 2021

Immune privilege or inflammation? Insights into the Fas ligand enigma

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

7 January 2021

Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

7 January 2021

A comparative study of Fas and Fas-ligand expression during melanoma progression

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

7 January 2021

Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

7 January 2021

Antitumor effect of locally produced CD95 ligand

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

7 January 2021

Tumor cells fight back to beat immune system

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

7 January 2021

Qualitative and quantitative contributions of the T cell receptor zeta chain to mature T cell apoptosis

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

7 January 2021

Fas and the art of lymphocyte maintenance

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

7 January 2021

Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

7 January 2021

Recognition of melanoma-derived antigens by CTL: possible mechanisms involved in down-regulating anti-tumor T-cell reactivity

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

7 January 2021

Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1(27-35)

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

7 January 2021

Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

7 January 2021

Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

7 January 2021

Interleukin 10-mediated immunosuppression by a variant CD4 T cell epitope of Plasmodium falciparum

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

7 January 2021

MHC antigens and tumor escape from immune surveillance

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

7 January 2021

Antitumor immunity at work in a melanoma patient

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

7 January 2021

Mechanisms of loss of HLA class I expression on colorectal tumor cells

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

7 January 2021

High frequency of altered HLA class I phenotypes in invasive colorectal carcinomas

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

7 January 2021

Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

7 January 2021

beta2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

7 January 2021

Mutations of the beta2-microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

7 January 2021

Beta 2-microglobulin gene mutations: a study of established colorectal cell lines and fresh tumors

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

7 January 2021

Selection for beta 2-microglobulin mutation in mismatch repair-defective colorectal carcinomas.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

7 January 2021

Analysis of HLA class I expression in different metastases from two melanoma patients undergoing peptide immunotherapy

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

7 January 2021

Chromosome loss is the most frequent mechanism contributing to HLA haplotype loss in human tumors

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

7 January 2021

Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

7 January 2021

A functionally defective allele of TAP1 results in loss of MHC class I antigen presentation in a human lung cancer

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

7 January 2021

Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

7 January 2021

Heterogeneous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in vivo

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

7 January 2021

A novel autocrine pathway of tumor escape from immune recognition: melanoma cell lines produce a soluble protein that diminishes expression of the gene encoding the melanocyte lineage melan-A/MART-1 antigen through down-modulation of its promoter

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

7 January 2021

Melanoma antigen recognition by tumour-infiltrating T lymphocytes (TIL): effect of differential expression of melan-A/MART-1

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

7 January 2021

Mannose 6-phosphate/insulin-like growth factor II receptor is a death receptor for granzyme B during cytotoxic T cell-induced apoptosis.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

7 January 2021

The chemoresistance of human malignant melanoma: an update.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

7 January 2021

Nitric Oxide Inhibits Caspase-3 byS-Nitrosationin Vivo

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

7 January 2021

Nitric oxide protects cultured rat hepatocytes from tumor necrosis factor-alpha-induced apoptosis by inducing heat shock protein 70 expression

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-065X.2002.18809.X

7 January 2021

10.1034/J.1600-065X.2002.18809.X

Identifiers

DOI

1 reference

5 August 2017

1 reference